The complex relationship of serum adiponectin to COPD outcomes

Chest

Volumn 142, Issue 4, 2012, Pages 893-899

  Yoon, Ho Il ^a,b   Li, Yuexin ^a   Man, S F Paul ^a   Tashkin, Donald ^c   Wise, Robert A ^d   Connett, John E ^e   Anthonisen, Nicholas A ^f   Churg, Andrew ^a   Wright, Joanne L ^a   Sin, Don D ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Seoul National University Bundang Hospital   (South Korea)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRONCHUS REACTIVITY; CANCER MORTALITY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SMOKING;

EID: 84867129700     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-2173     Document Type: Article

References (28)

1. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. Lancet. 2007;370(9589):741-750. (Pubitemid 47321907)
2. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet. 1997;349(9063):1436- 1442. (Pubitemid 27212192)
3. Gross NJ. Extrapulmonary effects of chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2001;7(2):84-92. (Pubitemid 32260651)
4. Ionescu AA, Schoon E. Osteoporosis in chronic obstructive pulmonary disease. Eur Respir J. 2003;22(suppl 46):64s-75s. (Pubitemid 37351738)
5. Rabe KF. Treating COPD: The TORCH trial, P values, and the Dodo [published correction appears in N Engl J Med. 2007;356(16):1692]. N Engl J Med. 2007;356(8):851-854. (Pubitemid 46294618)
6. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol. 2003;148(3):293-300. (Pubitemid 36410714)
7. Nakanishi K, Takeda Y, Tetsumoto S, et al. Involvement of endothelial apoptosis underlying chronic obstructive pulmonary disease-like phenotype in adiponectin-null mice: implications for therapy. Am J Respir Crit Care Med. 2011;183(9):1164-1175.
8. Kirdar S, Serter M, Ceylan E, Sener AG, Kavak T, Karadag F. Adiponectin as a biomarker of systemic inflammatory response in smoker patients with stable and exacerbation phases of chronic obstructive pulmonary disease. Scand J Clin Lab Invest. 2009;69(2):219-224.
9. Chan KH, Yeung SC, Yao TJ, et al. Elevated plasma adiponectin levels in patients with chronic obstructive pulmonary disease. Int J Tuberc Lung Dis. 2010;14(9):1193-1200.
10. Man SFP, Xing L, Connett JE, et al. Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD? Eur Respir J. 2008;32(6):1451-1457.
11. Sin DD, Miller BE, Duvoix A, et al. Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;183(9):1187-1192.
12. Wise RA, Kanner RE, Lindgren P, et al. The effect of smoking intervention and an inhaled bronchodilator on airways reactivity in COPD: the Lung Health Study. Chest. 2003;124(2):449-458. (Pubitemid 37000119)
13. Churg A, Zhou S, Wang X, Wang R, Wright JL. The role of interleukin-1beta in murine cigarette smoke-induced emphysema and small airway remodeling. Am J Respir Cell Mol Biol. 2009;40(4):482-490.
14. Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol. 2010;316(2):129-139.
15. Coppola A, Marfella R, Coppola L, et al. Effect of weight loss on coronary circulation and adiponectin levels in obese women. Int J Cardiol. 2009;134(3):414-416.
16. Ukkola O, Santaniemi M. Adiponectin: a link between excess adiposity and associated comorbidities? J Mol Med. 2002;80(11):696-702. (Pubitemid 35352035)
17. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003;423(6941):762-769. (Pubitemid 36735700)
18. Yamauchi T, Nio Y, Maki T, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med. 2007;13(3):332-339. (Pubitemid 46376688)
19. Miller M, Cho JY, Pham A, Ramsdell J, Broide DH. Adiponectin and functional adiponectin receptor 1 are expressed by airway epithelial cells in chronic obstructive pulmonary disease. J Immunol. 2009;182(1):684-691.
20. Tomoda K, Yoshikawa M, Itoh T, et al. Elevated circulating plasma adiponectin in underweight patients with COPD. Chest. 2007;132(1):135-140. (Pubitemid 47068213)
21. Waschki B, Kirsten A, Holz O, Muller K-C, Meyer T, Watz H, et al. Physical activity is the strongest predictor of all-cause mortality in patients with chronic obstructive pulmonary disease: a prospective cohort study. Chest. 2011;140(2):331-342.
22. Yamauchi T, Kadowaki T. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes (Lond). 2008;32(suppl 7):S13-S18.
23. Qi Y, Takahashi N, Hileman SM, et al. Adiponectin acts in the brain to decrease body weight. Nat Med. 2004;10(5):524-529. (Pubitemid 38667912)
24. Fruebis J, Tsao T-S, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A. 2001;98(4):2005-2010. (Pubitemid 32165613)
25. Jee SH, Sull JW, Park J, et al. Body-mass index and mortality in Korean men and women. N Engl J Med. 2006;355(8):779-787. (Pubitemid 44285583)
26. Nakanishi K, Takeda Y, Tetsumoto S, Iwasaki T, Tsujino K, Kuhara H, et al. Involvement of endothelial apoptosis underlying chronic obstructive pulmonary disease-like phenotype in adiponectin-null mice: implications for therapy. Am J Respir Crit Care Med. 2011;183(9):1164-1175.
27. Miller M, Pham A, Cho JY, Rosenthal P, Broide DH. Adiponectin-deficient mice are protected against tobacco-induced inflammation and increased emphysema. Am J Physiol Lung Cell Mol Physiol. 2010;299(6):L834-L42.
28. Johnston AK, Mannino DM, Hagan GW, Davis KJ, Kiri VA. Relationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle-aged cohort. Thorax. 2008;63(7):599-605. (Pubitemid 351969252)